During an extraordinary hearing Tuesday, members of a Senate subcommittee called for aggressive regulation of generative AI tools — and the makers and users of the technologies themselves urged the senators to quickly follow through.
“Regulatory intervention by governments will be critical to mitigate the risks of increasingly powerful models,” said Sam Altman, the CEO of OpenAI, the company behind ChatGPT. “The U.S. government might consider a combination of licensing and testing requirements for development and release of AI models above a threshold of capabilities.”
That consensus, which stands in stark contrast to the frequent clashes between U.S. lawmakers and tech industry leaders, comes as health care companies race to incorporate increasingly powerful AI tools into their businesses and interactions with patients.
This article is exclusive to STAT+ subscribers
Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect